SIRT2-IN-9 (compound 12) 是 SRIT2 的选择性抑制剂，IC50 值为 1.3 μM。SIRT2-IN-9 抑制 MCF-7 乳腺癌细胞的增殖活性。SIRT2-IN-9 可用于癌症的研究。
| Cas No. | 522650-91-5 |
| 分子式 | C21H22N6OS2 |
| 分子量 | 438.57 |
| 溶解度 | DMSO : 4.46 mg/mL (10.17 mM; ultrasonic and warming and heat to 70°C) |
| 储存条件 | 4°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | SIRT2-IN-9 (compound 12) is a selective inhibitor ofSRIT2with anIC50value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1]. SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC50value of 1.3 μM, and inhibits SRIT1 and SRIT3 with IC50s ＞300 μM[1].
SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells[1].
SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein[1]. Cell Proliferation Assay[1] | Cell Line: | MCF-7 breast cancer cell line | | Concentration: | 0-50 μM | | Incubation Time: | 72 hours | | Result: | Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells. |
Western Blot Analysis[1] | Cell Line: | MCF-7 breast cancer cell line | | Concentration: | 6.25, 12.5, 25 and 50 μM | | Incubation Time: | 6 hours | | Result: | Dose-dependently increased acetylation of α-tubulin protein. |
|
